Russell Investments Group Ltd. Acquires 28,460 Shares of LeMaitre Vascular Inc (LMAT)

Russell Investments Group Ltd. grew its holdings in LeMaitre Vascular Inc (NASDAQ:LMAT) by 24.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 145,958 shares of the medical instruments supplier’s stock after purchasing an additional 28,460 shares during the quarter. Russell Investments Group Ltd.’s holdings in LeMaitre Vascular were worth $4,887,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of LeMaitre Vascular in the 1st quarter valued at approximately $600,000. Principal Financial Group Inc. raised its holdings in LeMaitre Vascular by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 122,808 shares of the medical instruments supplier’s stock worth $4,449,000 after buying an additional 2,959 shares during the period. Conestoga Capital Advisors LLC raised its holdings in LeMaitre Vascular by 8.9% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,392,591 shares of the medical instruments supplier’s stock worth $46,624,000 after buying an additional 113,705 shares during the period. Quantitative Systematic Strategies LLC acquired a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $263,000. Finally, Piedmont Investment Advisors LLC acquired a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $119,000. Institutional investors and hedge funds own 79.76% of the company’s stock.

LMAT has been the topic of several research analyst reports. BidaskClub downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Friday, June 8th. Roth Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, June 8th. They set a “buy” rating and a $38.00 target price on the stock. ValuEngine upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, June 15th. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Monday, June 25th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Canaccord Genuity raised their target price on shares of LeMaitre Vascular from $31.00 to $35.00 and gave the stock a “hold” rating in a report on Monday, July 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. LeMaitre Vascular presently has a consensus rating of “Hold” and an average target price of $38.00.

In other news, Chairman George W. Lemaitre sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $37.07, for a total transaction of $556,050.00. Following the completion of the transaction, the chairman now directly owns 3,073,802 shares of the company’s stock, valued at approximately $113,945,840.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman George W. Lemaitre sold 14,180 shares of the firm’s stock in a transaction that occurred on Wednesday, August 22nd. The stock was sold at an average price of $37.61, for a total transaction of $533,309.80. Following the transaction, the chairman now directly owns 3,118,266 shares of the company’s stock, valued at $117,277,984.26. The disclosure for this sale can be found here. Insiders have sold a total of 112,506 shares of company stock valued at $4,164,809 over the last ninety days. Company insiders own 20.30% of the company’s stock.

Shares of LMAT stock opened at $34.69 on Friday. The company has a market cap of $665.12 million, a price-to-earnings ratio of 40.34, a P/E/G ratio of 2.15 and a beta of 0.60. LeMaitre Vascular Inc has a 52 week low of $28.23 and a 52 week high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.21). The business had revenue of $27.02 million for the quarter, compared to the consensus estimate of $27.09 million. LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%. LeMaitre Vascular’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.23 earnings per share. equities analysts anticipate that LeMaitre Vascular Inc will post 1.07 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 6th. Stockholders of record on Wednesday, August 22nd were paid a dividend of $0.07 per share. The ex-dividend date was Tuesday, August 21st. This represents a $0.28 annualized dividend and a dividend yield of 0.81%. LeMaitre Vascular’s dividend payout ratio is currently 32.56%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Story: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply